Breast cancer tumor markers: Worthless or beneficial?

Cancer Detection and Prevention

Volumn 32, Issue 3, 2008, Pages 188-189

  Elliott, Robert L ^a   Head, Jonathan F ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; HORMONE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; MICROMETASTASIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIODIAGNOSIS;

EID: 52949087529     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2008.08.007     Document Type: Note

References (6)

1. Khatcheressian J.L., Wolff A.C., Smith T.J., Grunfeld E., Muss H.B., Vogel V.G., et al. American Society of Clinical Oncology/2006 update of the breast cancer follow-up management guidelines in the adjuvant setting. J Clin Oncol 24 (2006) 5091-5097
2. Molina R., Barak V., VanDalen A., Duffy M.J., Einarsson R., Gion M., et al. Tumor markers in breast cancer European Group on tumor marker recommendations. Tumor Biol 26 (2005) 281-293
3. Duffy M.J. Biochemical markers in breast cancer; which ones are clinically useful?. Clin Biochem 34 (2001) 347-352
4. Lauro S., Trasatti L., Bordin F., Lanzetta G., Bria E., Gelibter A., et al. Comparison of CEA, MCA CA 15-3 and CA 27. 29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 19 (1999) 3511-3515
5. Hou M.F., Chen Y.L., Tseng T.F., Lin C.M., Chen M.S., Huang C.J., et al. Evaluation of serum CA 27.29, CA 15-3, and CEA in patients with breast cancer. Kaohsiung J Med Sci 15 (1999) 520-528
6. Jensen J.L., Maclean G.D., and Suresh M.R. Possible utility of serum determinations of CA-125 and CA 27 29 in breast cancer management. Int J Biol Markers 6 (1991) 1-6